文献速递药物相互作用治疗药物监测与药物基因组学抗栓抗凝管理

直接口服抗凝药群体药代动力学模型的系统综述与暴露模拟临床评价

Population Pharmacokinetic Models for Direct Oral Anticoagulants: A Systematic Review and Clinical Appraisal Using Exposure Simulation.
PubMed 文献 · Clin Pharmacol Ther · 2022-06-09

该研究系统识别了达比加群、阿哌沙班、利伐沙班和艾多沙班四种常用直接口服抗凝药(DOAC)的群体药代动力学(PopPK)模型,并利用这些模型模拟不同临床场景下的DOAC血浆浓度-时间曲线。模型模拟结果证实了已知影响DOAC暴露的主要因素具有临床相关性,并支持当前已批准剂量调整方案(至少对房颤),同时提示多种看似影响轻微的协变量累积可导致血药浓度超治疗范围并可能增加大出血风险。

要点

  • PopPK模型模拟支持当前DOAC在房颤中的剂量调整方案。
  • 多种轻微影响协变量累积可致DOAC血药浓度超治疗范围。
  • 药物相互作用或基因型等协变量累积时需重新审视剂量调整。

核心结论

  • 模型模拟结果证实已知影响DOAC暴露的主要因素具有临床相关性,并支持当前至少对房颤的已批准剂量调整。
  • 多种当前未因影响轻微而考虑用于剂量调整的协变量累积可导致超治疗血药浓度并可能增加大出血风险。
  • 结果对在已知协变量之外存在药物相互作用或基因型等协变量时的DOAC剂量调整提出质疑。

研究设计与样本

  • 系统综述,识别迄今四种最常用DOAC(达比加群、阿哌沙班、利伐沙班、艾多沙班)的所有PopPK模型。
  • 利用识别出的模型模拟相关临床场景下不同DOAC的血浆浓度-时间曲线。

主要发现

  • 模型模拟证实了已知主要因素对DOAC暴露影响的临床相关性。
  • 多种协变量累积(包括当前未考虑用于剂量调整的轻微影响协变量)可导致超治疗血药浓度。
  • 超治疗血药浓度可能增强大出血风险。

临床怎么用

  • PopPK模型可作为精准给药的有益工具,改善DOAC的个体化处方。
  • 临床应考虑多种协变量累积对DOAC暴露的潜在影响,而不仅关注已知主要因素。
  • 对存在药物相互作用或基因型等协变量的患者,需重新评估当前剂量调整策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Available data have shown an association between direct oral anticoagulant (DOAC) plasma concentration and clinical, particularly bleeding, events. Factors that may influence DOAC plasma concentration are therefore the focus of particular attention. Population pharmacokinetic (PopPK) analyses can help in identifying such factors while providing predictive models. The main aim of the present study was to identify all the PopPK models to date for the four most frequently used DOACs (dabigatran, apixaban, rivaroxaban, and edoxaban). The secondary aim was to use these models to simulate different DOAC plasma concentration-time profiles in relevant clinical scenarios. The results of our model-based simulations confirm the clinical relevance of the known major factors influencing DOAC exposure and support the current approved dose adaptation, at least for atrial fibrillation. They also highlight how the accumulation of covariates, not currently considered for dose adaptation due to their seemingly minor influence on DOAC exposure, lead to supratherapeutic blood concentrations and could thus enhance the risk of major bleeding. The present results therefore question DOAC dose adaptation in the presence of these covariates, such as drug-drug interaction or genotypes, alongside the known existing covariates. As the overall effect of accumulation of several covariates could be difficult to apprehend for the clinicians, PopPK modeling could represent an interesting approach for informed precision dosing and to improve personalized prescription of DOACs.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Terrier J, Gaspar F, Guidi M, et al. Population Pharmacokinetic Models for Direct Oral Anticoagulants: A Systematic Review and Clinical Appraisal Using Exposure Simulation. Clin Pharmacol Ther. 2022. PMID: 35593020. doi:10.1002/cpt.2649

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。